Trial Profile

A Multicenter, Open-label, Phase 1a Study of HC-5404-FU in Subjects With Advanced Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs HC 5404 (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Carcinoma; Colorectal cancer; Gastric cancer; HER2 positive breast cancer; Male breast cancer; Non-small cell lung cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors HiberCell

Most Recent Events

04 Jun 2024 Results assessing safety and efficacy of HC 5404 in patients with advanced solid tumors presented at the 60th Annual Meeting of the American Society of Clinical Oncology
27 Nov 2023 Status changed from recruiting to completed, according to a HiberCell media release.
27 Nov 2023 According to a HiberCell media release, interim data from this trial was published in the AACR, Clinical Cancer Research (CCR).

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com